CalciMedica, Inc. (CALC) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US38942Q2021
CalciMedica, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -23.12 m USD |
| EBIT | -28.14 m USD |
| Net income | -29.56 m USD |
| Diluted EPS – continuing operations | -1.97 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
More stocks
- AETERNUM HEALTH, INC. (AETN)
- ACCURAY INC (ARAY)
- INNOVATIVE DESIGNS INC (IVDN)
- GREENLITE VENTURES INC (GRNL)
- Moleculin Biotech, Inc. (MBRX)
- Upland Software, Inc. (UPLD)
- Vistagen Therapeutics, Inc. (VTGN)
- Summit Networks Inc. (SNTW)
- INTRUSION INC (INTZ)
- Reborn Coffee, Inc. (REBN)
- Cardlytics, Inc. (CDLX)
- VPR Brands, LP. (VPRB)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.